ALNY
Alnylam Pharmaceuticals Inc

4,383
Mkt Cap
$58.49B
Volume
822,669.00
52W High
$495.55
52W Low
$205.87
PE Ratio
1,841.51
ALNY Fundamentals
Price
$442.70
Prev Close
$440.49
Open
$437.81
50D MA
$458.76
Beta
0.95
Avg. Volume
1.15M
EPS (Annual)
-$2.18
P/B
249.45
Rev/Employee
$1.01M
Loading...
Loading...
News
all
press releases
New Post Hoc Analysis from the HELIOS-B Phase 3 Study Shows Vutrisiran Improved Measures of Heart Structure and Function in Patients with ATTR-CM
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced results from new post hoc analyses of the HELIOS-B Phase 3 study of AMVUTTRA (vutrisiran), an RNAi...
Business Wire·8h ago
News Placeholder
More News
News Placeholder
Here's How Much $1000 Invested In Alnylam Pharmaceuticals 20 Years Ago Would Be Worth Today
read more...
Benzinga·1d ago
News Placeholder
What Does the Market Think About Alnylam Pharmaceuticals Inc?
read more...
Benzinga·2d ago
News Placeholder
Alnylam to Webcast Presentations at Upcoming November Investor Conferences
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following upcoming investor conferences: UBS...
Business Wire·5d ago
News Placeholder
ALNY Q3 Earnings and Revenues Top Estimates on Higher Amvuttra Sales
Alnylam's Q3 earnings and revenues surge past forecasts, powered by booming Amvuttra sales and a key milestone payment from Roche.
Zacks·9d ago
News Placeholder
Compared to Estimates, Alnylam (ALNY) Q3 Earnings: A Look at Key Metrics
Although the revenue and EPS for Alnylam (ALNY) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Zacks·10d ago
News Placeholder
Alnylam Pharmaceuticals (ALNY) Q3 Earnings and Revenues Top Estimates
Alnylam (ALNY) delivered earnings and revenue surprises of +73.65% and +22.25%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·10d ago
News Placeholder
Alnylam Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Period Progress
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the third quarter ended September 30, 2025 and reviewed...
Business Wire·10d ago
News Placeholder
Zoetis Gears Up to Report Q3 Earnings: Here's What to Expect
ZTS is poised for another earnings beat as rising demand for companion animal products like Simparica Trio and Apoquel drives expected Q3 revenue growth.
Zacks·10d ago
News Placeholder
Amgen's Q3 Earnings in the Cards: Here's What to Expect
Amgen's Q3 results are on deck, with growth from newer drugs offset by biosimilar competition and pricing pressures.
Zacks·11d ago

Latest ALNY News

View

Advertisement|Remove ads.

Advertisement|Remove ads.